BIRC5 and breast carcinoma: They also showed that treating different cancer cell lines [126], as well as melanoma [127] and breast cancer [126,128] xenografts with dominant-negative mutants of survivin resulted in suppression of tumor growth and angiogenesis [128] and augmentation of apoptotic responses.